1. Home
  2. VABK vs LXEO Comparison

VABK vs LXEO Comparison

Compare VABK & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virginia National Bankshares Corporation

VABK

Virginia National Bankshares Corporation

N/A

Current Price

$53.75

Market Cap

293.1M

Sector

Finance

ML Signal

N/A

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

N/A

Current Price

$3.04

Market Cap

348.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
VABK
LXEO
Founded
1998
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
293.1M
348.7M
IPO Year
2013
2023

Fundamental Metrics

Financial Performance
Metric
VABK
LXEO
Price
$53.75
$3.04
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $25.11
AVG Volume (30 Days)
15.1K
★ 2.5M
Earning Date
10-29-2026
11-16-2026
Dividend Yield
★ 3.11%
N/A
EPS Growth
12.70
★ 39.81
EPS
★ 3.82
N/A
Revenue
N/A
★ $654,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.95
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.35
$2.55
52 Week High
$55.00
$10.99

Technical Indicators

Market Signals
Indicator
VABK
LXEO
Relative Strength Index (RSI) 59.68 48.31
Support Level $46.61 $2.72
Resistance Level $55.00 $3.56
Average True Range (ATR) 1.15 0.40
MACD -0.04 0.02
Stochastic Oscillator 61.75 19.69

Price Performance

Historical Comparison
VABK
LXEO

About VABK Virginia National Bankshares Corporation

Virginia National Bankshares Corp is a bank holding company engaged in commercial and retail banking. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts, and other depository services. Its segments include the Bank, VNB Trust and Estate Services, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits, and offering related services to individuals, businesses, and charitable organizations.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Share on Social Networks: